Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice: A PBRN Clinical Trial

Status: Recruiting
Location: See location...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Periodontitis is a bacterial inflammatory disease and antibiotic use is being empirically used as part of its treatment. However, a clinical practice guideline on periodontal treatment adjuncts published in 2015 identified weak evidence on the use of systemic antibiotics and large heterogeneity across small scale studies, suggesting that larger pragmatic clinical trials would benefit clinical decision making. This will be a prospective, randomized, placebo-controlled trial, stratified by practice and practitioner. The study will investigate the effectiveness of adjunctive antibiotics as adjunct to scaling and root planing (SRP) compared to SRP with placebo for the treatment of generalized stage II-III, grades A-C periodontitis in patient participants from National Dental PBRN practices. Periodontal data will be collected at baseline, re-evaluation (6 weeks), and final (4-12 months) study visits. Changes in periodontal clinical and patient-reported outcomes will be assessed to determine the effectiveness of SRP plus adjunctive systemic Amoxicillin / Metronidazole antibiotics (AMXM) versus SRP with Placebo.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 35
Healthy Volunteers: t
View:

• The study will recruit patient participants presenting for periodontal treatment within the National Dental PBRN practices participating in this study.

⁃ To be eligible to participate in this study, a potential patient participant must meet all the following criteria:

• Adult who is at least 35 years old.

• Presence of ≥ 15 permanent teeth excluding 3rd molars.

• In good general health as evidenced by medical history (ASA Class I or II) per the practitioner.

• Planned to receive periodontal care for Generalized Periodontitis and a minimum of two quadrants of SRP (CDT code 4341) in practices participating in the National Dental PBRN.

• Willing to comply with all study visits and be available for the duration of the study (12-15 months)

• Willing to provide contact information for self, including a cellular phone number for study text, and one to two emergency contacts to be reached for the follow-up visits and any other study-related matters for the duration of the study.

Locations
United States
Alabama
University of Alabame
RECRUITING
Birmingham
Contact Information
Primary
Varvara Chrepa, DDS, PhD
vc551@sdm.rutgers.edu
973-972-7331
Time Frame
Start Date: 2024-04-25
Estimated Completion Date: 2026-05-26
Participants
Target number of participants: 150
Treatments
Experimental: Test Arm
Patient participants in this arm will receive a combination of Amoxicillin 500mg \& Metronidazole 500mg orally (AMXM) as adjuncts along with their scheduled non-surgical periodontal treatment as the study intervention. A loading dose of 1g of Amoxicillin and 1g of Metronidazole will be given 30-60 minutes prior to periodontal treatment. After the loading dose, each patient participant will be instructed to take Amoxicillin 500mg \& Metronidazole 500mg every 8 hours for 10 days.
Placebo_comparator: Control Arm
Patient participants in this arm will receive a placebo capsules identical to the study drug capsules along with their scheduled non-surgical periodontal treatment as the placebo comparator in an identical frequency and duration fashion as the active drug group.
Related Therapeutic Areas
Sponsors
Leads: Rutgers, The State University of New Jersey
Collaborators: National Dental PBRN, National Institute of Dental and Craniofacial Research (NIDCR)

This content was sourced from clinicaltrials.gov